These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 35544137)

  • 1. Comparison of Bayesian vs Frequentist Adaptive Trial Design in the Stroke Hyperglycemia Insulin Network Effort Trial.
    Broglio K; Meurer WJ; Durkalski V; Pauls Q; Connor J; Berry D; Lewis RJ; Johnston KC; Barsan WG
    JAMA Netw Open; 2022 May; 5(5):e2211616. PubMed ID: 35544137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Stroke Hyperglycemia Insulin Network Effort (SHINE) trial: an adaptive trial design case study.
    Connor JT; Broglio KR; Durkalski V; Meurer WJ; Johnston KC
    Trials; 2015 Mar; 16():72. PubMed ID: 25885963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do we need to adjust for interim analyses in a Bayesian adaptive trial design?
    Ryan EG; Brock K; Gates S; Slade D
    BMC Med Res Methodol; 2020 Jun; 20(1):150. PubMed ID: 32522284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Over-accrual in Bayesian adaptive trials with continuous futility stopping.
    Barrado LG; Burzykowski T
    Clin Trials; 2023 Jun; 20(3):252-260. PubMed ID: 36803007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Bayesian and frequentist monitoring boundaries motivated by the Multiplatform Randomized Clinical Trial.
    Joo J; Leifer ES; Proschan MA; Troendle JF; Reynolds HR; Hade EA; Lawler PR; Kim DY; Geller NL
    Clin Trials; 2024 Dec; 21(6):701-709. PubMed ID: 38760932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian group sequential designs for phase III emergency medicine trials: a case study using the PARAMEDIC2 trial.
    Ryan EG; Stallard N; Lall R; Ji C; Perkins GD; Gates S
    Trials; 2020 Jan; 21(1):84. PubMed ID: 31937351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian and frequentist approaches to sequential monitoring for futility in oncology basket trials: A comparison of Simon's two-stage design and Bayesian predictive probability monitoring with information sharing across baskets.
    Kaizer A; Zabor E; Nie L; Hobbs B
    PLoS One; 2022; 17(8):e0272367. PubMed ID: 35917296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian Interim Analysis and Efficiency of Phase III Randomized Trials.
    Sherry AD; Msaouel P; Miller AM; Lin TA; Kupferman GS; Jaoude JA; Kouzy R; El-Alam MB; Patel R; Koong A; Lin C; Meirson T; McCaw ZR; Ludmir EB
    medRxiv; 2024 Jun; ():. PubMed ID: 38978666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Bayesian and frequentist group-sequential clinical trial designs.
    Stallard N; Todd S; Ryan EG; Gates S
    BMC Med Res Methodol; 2020 Jan; 20(1):4. PubMed ID: 31910813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensive vs Standard Treatment of Hyperglycemia and Functional Outcome in Patients With Acute Ischemic Stroke: The SHINE Randomized Clinical Trial.
    Johnston KC; Bruno A; Pauls Q; Hall CE; Barrett KM; Barsan W; Fansler A; Van de Bruinhorst K; Janis S; Durkalski-Mauldin VL;
    JAMA; 2019 Jul; 322(4):326-335. PubMed ID: 31334795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal futility stopping boundaries for binary endpoints.
    Freitag MM; Li X; Rauch G
    BMC Med Res Methodol; 2024 Mar; 24(1):80. PubMed ID: 38539108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adaptive designs in critical care trials: a simulation study.
    Li W; Cornelius V; Finfer S; Venkatesh B; Billot L
    BMC Med Res Methodol; 2023 Oct; 23(1):236. PubMed ID: 37853343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-stage randomized clinical trials with a right-censored endpoint: Comparison of frequentist and Bayesian adaptive designs.
    Boumendil L; Chevret S; Lévy V; Biard L
    Stat Med; 2024 Aug; 43(18):3364-3382. PubMed ID: 38844988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interpreting a Bayesian phase II futility clinical trial.
    Beall J; Cassarly C; Martin R
    Trials; 2022 Nov; 23(1):953. PubMed ID: 36414953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using Bayesian adaptive designs to improve phase III trials: a respiratory care example.
    Ryan EG; Bruce J; Metcalfe AJ; Stallard N; Lamb SE; Viele K; Young D; Gates S
    BMC Med Res Methodol; 2019 May; 19(1):99. PubMed ID: 31088354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequentist operating characteristics of Bayesian optimal designs via simulation.
    Zhang Y; Trippa L; Parmigiani G
    Stat Med; 2019 Sep; 38(21):4026-4039. PubMed ID: 31215685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian adaptive design for pediatric clinical trials incorporating a community of prior beliefs.
    Wang Y; Travis J; Gajewski B
    BMC Med Res Methodol; 2022 Apr; 22(1):118. PubMed ID: 35448963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review of randomised controlled trials with adaptive and traditional group sequential designs - applications in cardiovascular clinical trials.
    Zhang J; Saju C
    BMC Med Res Methodol; 2023 Sep; 23(1):200. PubMed ID: 37679710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel Bayesian adaptive design incorporating both primary and secondary endpoints for randomized IIB chemoprevention study of women at increased risk for breast cancer.
    Gajewski BJ; Kimler BF; Koestler DC; Mudaranthakam DP; Young K; Fabian CJ
    Trials; 2022 Dec; 23(1):981. PubMed ID: 36471449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.